within Pharmacolibrary.Drugs.ATC.C;

model C10BX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10BX09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rosuvastatin and amlodipine is a fixed-dose combination drug used in the management of cardiovascular diseases like hypertension and hypercholesterolemia. Rosuvastatin is a statin that lowers cholesterol, while amlodipine is a calcium channel blocker for hypertension. The fixed-dose combination (ATC code: C10BX09) is approved and used in clinical practice for adults as adjunct therapy to diet and exercise to reduce risk of cardiovascular events.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models for the fixed combination C10BX09 identified. Parameter estimates below are based on individual drug literature and standard adult population, oral administration.</p><h4>References</h4><ol><li><p>Moon, SJ, et al., &amp; Kim, MG (2019). Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. <i>Drug design, development and therapy</i> 13 2533–2542. DOI:<a href=\"https://doi.org/10.2147/DDDT.S210364\">10.2147/DDDT.S210364</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31440035/\">https://pubmed.ncbi.nlm.nih.gov/31440035</a></p></li><li><p>Yoon, DY, et al., &amp; Chung, JY (2020). Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. <i>Drug design, development and therapy</i> 14 661–668. DOI:<a href=\"https://doi.org/10.2147/DDDT.S233014\">10.2147/DDDT.S233014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32109991/\">https://pubmed.ncbi.nlm.nih.gov/32109991</a></p></li><li><p>Park, JS, et al., &amp; Kim, MG (2019). Pharmacokinetic and bioequivalence study of a fixed-dose combination of amlodipine besylate and rosuvastatin calcium compared to co-administration of separate tablets in healthy Korean subjects . <i>International journal of clinical pharmacology and therapeutics</i> 57(12) 612–622. DOI:<a href=\"https://doi.org/10.5414/CP203554\">10.5414/CP203554</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31549624/\">https://pubmed.ncbi.nlm.nih.gov/31549624</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10BX09;
